JCR Pharmaceuticals Co., Ltd. (JCRRF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
JCR Pharmaceuticals Co., Ltd. (JCRRF) with AI Score 48/100 (Weak). JCR Pharmaceuticals Co. , Ltd. is a specialty pharmaceuticals company based in Japan, focusing on regenerative medicines and therapeutic products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026JCR Pharmaceuticals Co., Ltd. (JCRRF) Healthcare & Pipeline Overview
JCR Pharmaceuticals Co., Ltd. specializes in innovative therapeutic solutions, including regenerative medicines and treatments for rare diseases, positioning itself as a key player in the Japanese pharmaceutical market with a strong focus on patient-centric care.
Investment Thesis
JCR Pharmaceuticals Co., Ltd. presents a compelling investment thesis driven by its strong product pipeline and established market presence in Japan. With a market cap of $0.51 billion and a gross margin of 70%, the company is well-positioned to capitalize on the growing demand for specialty pharmaceuticals. Key growth catalysts include the expansion of its therapeutic offerings, particularly in regenerative medicine, which is projected to grow significantly in the coming years. Furthermore, the company's focus on rare diseases aligns with industry trends favoring specialized treatments, potentially enhancing its competitive advantage. However, investors should remain cautious of the company's negative profit margin of -6.5% and ongoing risks associated with regulatory approvals and market competition.
Based on FMP financials and quantitative analysis
Key Highlights
- Market cap of $0.51 billion, indicating a stable presence in the specialty pharmaceuticals sector.
- Gross margin of 70.0%, reflecting strong pricing power and operational efficiency.
- Negative profit margin of -6.5%, highlighting potential challenges in achieving profitability.
- P/E ratio of -30.26, indicating current losses but potential for future growth.
- Dividend yield of 3.31%, providing a return to shareholders despite operational challenges.
Competitors & Peers
Strengths
- Strong product portfolio with a focus on niche therapeutic areas.
- High gross margin indicating strong operational efficiency.
- Established presence in the Japanese pharmaceutical market.
- Robust R&D capabilities leading to innovative therapies.
Weaknesses
- Negative profit margin indicating current operational challenges.
- Dependence on a limited number of key products for revenue.
- Potential vulnerability to regulatory changes affecting drug approvals.
- Limited international presence compared to larger competitors.
Catalysts
- Upcoming: Launch of new therapeutic products targeting rare diseases.
- Ongoing: Expansion of clinical trials for Epoetin Alfa BS and Darbepoetin Alfa BS injections.
- Upcoming: Strategic partnerships to enhance R&D capabilities and product development.
- Ongoing: Continuous improvement in operational efficiencies to enhance margins.
- Upcoming: Potential regulatory approvals for new drug applications.
Risks
- Potential: Regulatory hurdles that may delay product launches.
- Ongoing: Competition from larger pharmaceutical companies in the specialty sector.
- Potential: Risks associated with the development of new therapies and clinical trials.
- Ongoing: Market volatility affecting the company's financial performance.
Growth Opportunities
- Growth opportunity 1: The global market for regenerative medicine is projected to reach $100 billion by 2030, driven by advancements in cell therapy and tissue engineering. JCR Pharmaceuticals can leverage its expertise in regenerative medicines to capture a significant share of this growing market, particularly with its TEMCELL product, which addresses acute graft-versus-host disease.
- Growth opportunity 2: The increasing prevalence of rare diseases presents a substantial opportunity for JCR Pharmaceuticals. With a growing focus on orphan drugs, the company can expand its product offerings in this area, particularly with treatments like IZCARGO for Mucopolysaccharidosis type II, which addresses unmet medical needs.
- Growth opportunity 3: The aging population in Japan is driving demand for treatments related to age-associated conditions, including renal anemia. JCR Pharmaceuticals’ development of Epoetin Alfa BS and Darbepoetin Alfa BS injections positions the company to meet this rising demand, potentially increasing its market share in the renal treatment segment.
- Growth opportunity 4: Strategic partnerships and collaborations with research institutions can enhance JCR Pharmaceuticals' R&D capabilities. By engaging in joint ventures, the company can accelerate the development of innovative therapies and expand its pipeline, thereby increasing its competitive advantage in the market.
- Growth opportunity 5: Expansion into international markets could provide JCR Pharmaceuticals with new revenue streams. As the company continues to develop its product portfolio, exploring opportunities in regions with high unmet medical needs can significantly enhance its growth trajectory.
Opportunities
- Growing demand for regenerative medicines and orphan drugs.
- Expansion into international markets to capture new revenue streams.
- Strategic partnerships to enhance R&D capabilities.
- Increasing prevalence of rare diseases providing market opportunities.
Threats
- Intense competition from both established and emerging pharmaceutical companies.
- Regulatory hurdles that may delay product approvals.
- Market volatility affecting funding and investment in R&D.
- Potential for biosimilar competition impacting pricing strategies.
Competitive Advantages
- Strong focus on niche therapeutic areas, providing a competitive edge in specialized markets.
- Established reputation and brand recognition within the Japanese pharmaceutical industry.
- Robust R&D capabilities leading to innovative product development.
- High gross margins indicative of pricing power and operational efficiency.
- Regulatory compliance and expertise in navigating the pharmaceutical landscape.
About JCRRF
Founded in 1975, JCR Pharmaceuticals Co., Ltd. is headquartered in Ashiya, Japan. The company has established itself as a leader in the specialty pharmaceuticals sector, focusing on the research, development, manufacture, import, and export of pharmaceutical products and regenerative medicines. JCR Pharmaceuticals has developed a diverse portfolio of therapeutic products, including GROWJECT for growth hormone deficiency, IZCARGO for Mucopolysaccharidosis type II, Agalsidase Beta BS I.V. Infusion for Fabry disease, and TEMCELL HS Inj for acute graft-versus-host disease. Additionally, the company is advancing its pipeline with Epoetin Alfa BS and Darbepoetin Alfa BS injections aimed at treating renal anemia. JCR Pharmaceuticals not only develops drugs but also sells medical devices and laboratory instruments, enhancing its market presence. With a workforce of 934 employees, the company is committed to improving patient outcomes through innovative therapies and has positioned itself strategically in the Japanese healthcare market, where it continues to expand its reach and impact.
What They Do
- Research and develop pharmaceutical products and regenerative medicines.
- Manufacture and sell therapeutic products for various medical conditions.
- Import and export pharmaceutical products to and from Japan.
- Provide medical devices and laboratory instruments.
- Focus on niche therapeutic areas, including rare diseases and regenerative medicine.
- Engage in clinical trials to advance its product pipeline.
Business Model
- Revenue generated through the sale of pharmaceutical products and regenerative medicines.
- Income from manufacturing and selling medical devices and laboratory instruments.
- Import and export activities contributing to overall sales.
- Potential revenue from licensing agreements and partnerships in R&D.
- Focus on niche markets allows for premium pricing strategies.
Industry Context
The drug manufacturing industry, particularly in the specialty pharmaceuticals sector, is experiencing significant growth driven by an increasing demand for targeted therapies and regenerative medicines. The global market for regenerative medicine is expected to expand at a CAGR of over 20% through the next decade, reflecting a robust trend toward personalized medicine. JCR Pharmaceuticals Co., Ltd. is well-positioned within this landscape, focusing on niche therapeutic areas such as rare diseases, which are often underserved. The competitive landscape includes several peers, such as AGYTF, AVNBF, BJTRF, BOIRF, and GLASF, all vying for market share in this dynamic environment.
Key Customers
- Healthcare providers and hospitals requiring specialized pharmaceutical products.
- Patients with rare diseases seeking effective treatments.
- Research institutions needing laboratory instruments and medical devices.
- Pharmaceutical distributors and wholesalers.
- Government and regulatory bodies involved in healthcare provision.
Financials
Chart & Info
JCR Pharmaceuticals Co., Ltd. (JCRRF) stock price: Price data unavailable
Latest News
No recent news available for JCRRF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JCRRF.
Price Targets
Wall Street price target analysis for JCRRF.
MoonshotScore
What does this score mean?
The MoonshotScore rates JCRRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shin Ashida
CEO
Shin Ashida has extensive experience in the pharmaceutical industry, having held various leadership roles in both domestic and international markets. He holds a degree in Pharmaceutical Sciences and has been instrumental in driving JCR Pharmaceuticals' strategic vision and growth since taking the helm.
Track Record: Under Shin Ashida's leadership, JCR Pharmaceuticals has expanded its product offerings and strengthened its market position. His strategic focus on R&D and innovative therapies has led to the successful launch of several key products, enhancing the company's reputation in the specialty pharmaceuticals sector.
JCRRF OTC Market Information
The OTC Other tier indicates that JCR Pharmaceuticals Co., Ltd. trades on the over-the-counter market, which generally has less stringent reporting requirements compared to major exchanges like NYSE or NASDAQ. This tier can include companies that are smaller or have less liquidity, making it essential for investors to conduct thorough due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower regulatory oversight compared to stocks listed on major exchanges.
- Potential for higher volatility and lower trading volumes.
- Limited availability of financial information and disclosures.
- Increased risk of fraud or misrepresentation in less regulated markets.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Understand the competitive landscape and market positioning.
- Evaluate the product pipeline and potential growth opportunities.
- Monitor regulatory developments that could impact the business.
- Established history since 1975, indicating stability and experience.
- Presence of a dedicated management team with industry expertise.
- Product portfolio addressing significant medical needs, enhancing credibility.
- Compliance with Japanese pharmaceutical regulations and standards.
What Investors Ask About JCR Pharmaceuticals Co., Ltd. (JCRRF)
What does JCR Pharmaceuticals Co., Ltd. do?
JCR Pharmaceuticals Co., Ltd. is a specialty pharmaceuticals company engaged in the research, development, manufacture, import, and export of pharmaceutical products and regenerative medicines. The company offers a range of therapeutic products aimed at treating various medical conditions, including growth hormone deficiency, Fabry disease, and acute graft-versus-host disease.
What do analysts say about JCRRF stock?
Analysts have mixed views on JCR Pharmaceuticals Co., Ltd. stock, reflecting concerns about its negative profit margin and ongoing operational challenges. However, the company's strong gross margin and focus on niche therapeutic areas are seen as positive factors. Investors are encouraged to monitor the company's product pipeline and market developments closely.
What are the main risks for JCRRF?
JCR Pharmaceuticals Co., Ltd. faces several risks, including regulatory hurdles that could impact product approvals and market entry. Additionally, the company operates in a competitive landscape with larger pharmaceutical firms, posing challenges for market share. Ongoing operational challenges, reflected in its negative profit margin, also present risks to financial performance.
What are the key factors to evaluate for JCRRF?
JCR Pharmaceuticals Co., Ltd. (JCRRF) currently holds an AI score of 48/100, indicating low score. Key strength: Strong product portfolio with a focus on niche therapeutic areas.. Primary risk to monitor: Potential: Regulatory hurdles that may delay product launches.. This is not financial advice.
How frequently does JCRRF data refresh on this page?
JCRRF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven JCRRF's recent stock price performance?
Recent price movement in JCR Pharmaceuticals Co., Ltd. (JCRRF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong product portfolio with a focus on niche therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider JCRRF overvalued or undervalued right now?
Determining whether JCR Pharmaceuticals Co., Ltd. (JCRRF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying JCRRF?
Before investing in JCR Pharmaceuticals Co., Ltd. (JCRRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information; future performance may vary.